Search research articles
Contact Us
Filters
Showing results (461-470 of 494) with videos related to
Page
of 50
Sort By:
Nature Communications
|
May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
Zhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Journal of Medicinal Chemistry
|
June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication
Renato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 29, 2011
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Renato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Cancer Research
|
February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Journal of Medicinal Chemistry
|
September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Conservation Biology : the Journal of the Society for Conservation Biology
|
November 22, 2018
Effects of life history and reproduction on recruitment time lags in reintroductions of rare plants
Matthew A Albrecht, Oyomoare L Osazuwa-Peters, Joyce Maschinski, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 5, 2008
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary, Dongguang Qin, Donna McEachern, et al.
Cancer Research
|
August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression
Shaomeng Wang, Wei Sun, Yujun Zhao, et al.
Page
of 50
Search research articles
Search
Showing results (461-470 of 494) with videos related to
Sort By:
Page
of 50
Nature Communications
|
May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
Zhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Journal of Medicinal Chemistry
|
June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication
Renato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 29, 2011
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Renato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Cancer Research
|
February 18, 2017
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai, Bing Zhou, Chao-Yie Yang, et al.
Journal of Medicinal Chemistry
|
September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
Weiguo Xiang, Lijie Zhao, Xin Han, et al.
Conservation Biology : the Journal of the Society for Conservation Biology
|
November 22, 2018
Effects of life history and reproduction on recruitment time lags in reintroductions of rare plants
Matthew A Albrecht, Oyomoare L Osazuwa-Peters, Joyce Maschinski, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 5, 2008
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary, Dongguang Qin, Donna McEachern, et al.
Cancer Research
|
August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression
Shaomeng Wang, Wei Sun, Yujun Zhao, et al.
Page
of 50